sleeping mouse made of cancer cell mass

Don't let sleeping cells lie

read about cancer and senescence in our October issue

  • Clemens A. Schmitt
  • Boshi Wang
  • Marco Demaria
Review Article


  • flow chart

    "Is early-onset cancer an emerging global epidemic? Current evidence and future implications" from T. Ugai et al. will be freely available during the month after the publication of our October 2022 issue

  • viral particles

    Read all the COVID-19-related contents published in our journal, which will be freely available during the pandemic


    • A high serum lactate dehydrogenase (LDH) level is generally associated with an inferior outcome in patients with most tumour types. LDH is also known to have immunosuppressive and/or tumour-promoting effects, suggesting a potentially broader role for this enzyme in clinical oncology. In this Review, the authors provide a holistic overview of the current role of LDH in both cancer biology and oncology, and highlight possible areas of future research interest, including the development of novel therapies targeting LDH.

      • Giuseppina Claps
      • Sara Faouzi
      • Caroline Robert
      Review Article
    • Clinical research needs support from preclinical models that consider the biology and genetics of human cancers during treatment, such as patient-derived xenograft (PDX) models. The authors of this Review discuss how PDX models have been used in the past decade for precision oncology and present emerging approaches that could broaden the application of these models.

      • Eugenia R. Zanella
      • Elena Grassi
      • Livio Trusolino
      Review Article
    • Glioblastoma, the most common form of brain cancer in adults, has a dismal prognosis and has proven recalcitrant to novel targeted therapies and immunotherapies. Extrachromosomal DNAs (ecDNAs) harbouring oncogenes are increasingly recognized as important drivers of tumour development, evolution and resistance to treatment, particularly in patients with glioblastoma. In this Perspective, the authors summarize key reasons for the failed clinical translation of new therapies for glioblastoma, highlighting the important contributions of ecDNAs. They then focus on the opportunities and challenges of utilizing ecDNAs to improve the likelihood of success in the development of precision medicines for this disease.

      • Imran Noorani
      • Paul S. Mischel
      • Charles Swanton
    • Peritoneal surface malignancies (PSMs) typically have a poor prognosis, although considerable advances in the understanding and management of these malignancies have been made over the past decade. This Review comprehensively describes the improvements in knowledge of the biology, assessment and classification, perioperative and surgical management, systemic treatment and pre-emptive management of PSMs. The authors also outline future directions for research in this field.

      • Vahan Kepenekian
      • Aditi Bhatt
      • Olivier Glehen
      Review Article
    • The incidence of early-onset forms of many cancers (defined as cancers diagnosed in individuals <50 years of age) has increased in a number of countries over the past several decades. The underlying reasons for this apparent increase probably include greater use of screening programmes, but also changing patterns in early-life exposures. In this Review, the authors describe the emerging global increase in the incidence of early-onset cancers and suggest changes that might address this situation.

      • Tomotaka Ugai
      • Naoko Sasamoto
      • Shuji Ogino
      Review Article

Nature Careers